OncoImmune raises $15M for PhII GvHD study; FDA wraps biosimilar naming guidance
• Rockville, MD-based OncoImmune has raised a $15 million Series A round. 3E Bioventures Capital led the round, which is primarily focused on a therapy that targets the CD24-Siglec pathway. The biotech believes they can follow this target to a new approach in regulating an inflammatory response to tissue injuries, playing a role in autoimmune diseases, cancer and graft-versus-host disease. The lead drug, CD24Fc, is going into Phase II for GvHD.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
